SCHEMBL12799037

SCHEMBL12799037

c1cc2[nH]c([C@@H]3CCCN3)nc2cc1-c1cnc(-c2ccc3nc([C@@H]4CCCN4)[nH]c3c2)o1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCN10A Q9Y5Y9 1/20 0.50
▸ DGAT1 O75907 1/20 0.42
▸ PARP1 P09874 5/20 0.37
▸ SNCA P37840 1/20 0.36
▸ TLR9 Q9NR96 1/20 0.35
▸ TLR8 Q9NR97 1/20 0.35
▸ TLR7 Q9NYK1 1/20 0.35
▸ NPY5R Q15761 2/20 0.34
▸ CHRNB2 P17787 1/20 0.34
▸ CHRNA4 P43681 1/20 0.34
▸ CDC7 O00311 4/20 0.34
▸ PIM1 P11309 3/20 0.34
▸ CSNK2B P67870 3/20 0.34
▸ CSNK2A1 P68400 3/20 0.34
▸ CIT O14578 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CSNK2A2 P19784 1/20 0.34
▸ GSK3B P49841 1/20 0.34
▸ DYRK1A Q13627 1/20 0.34
▸ CSNK2A3 Q8NEV1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12799036 0.91 SCN10A (0.43) SCN10ADGAT1PARP1SNCATLR9
SCHEMBL12798837 0.84 SCN10A (0.63) SCN10APARP1NPY5RCDC7CCNE1
SCHEMBL12799035 0.84 PARP1 (0.45) SCN10APARP1CHRNB2CHRNA4CDC7
SCHEMBL12798936 0.82 SCN10A (0.60) SCN10APARP1NPY5RCHRNB2CHRNA4
SCHEMBL12403439 0.82 SCN3A (0.47) SCN10APARP1CITCSNK2A2GSK3B
SCHEMBL10201555 0.81 DHODH (0.43) PARP1
SCHEMBL12403437 0.81 DHODH (0.43) PARP1
SCHEMBL12405016 0.80 DHODH (0.39) SCN10APARP1CYP1A2GSK3BDYRK1A
SCHEMBL12403445 0.80 SCN3A (0.37) SCN10APARP1GSK3BDYRK1ACCNE1
SCHEMBL1293911 0.80 SCN10A (0.58) SCN10APARP1NPY5RUSP30AAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7906655-B2 5,5'-(1,2-ethynediyl)bis(2-((2S)-1-((2R)-2-phenylpropanoyl)-2-pyrrolidinyl)-1H-benzimidazole); inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV); useful in establishing or determining the binding site of other antiviral compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2011-03-15 — — US disclosed
US-20100068176-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-03-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100068176-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, PYGL, HCCS SCN10A 4625/4885DGAT1 811/4885PARP1 3489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback